Current and future asthma therapies

Drugs of Today

Volumn 49, Issue 5, 2013, Pages 325-339

  Kandeel, M ^a,b   Balaha, M ^c   Inagaki, N ^d   Kitade, Y ^b  

^a Kafrelsheikh University   (Egypt)

^b GIFU UNIVERSITY   (Japan)

^c TANTA UNIVERSITY   (Egypt)

^d GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Asthma; Corticosteroids; Drug resistance

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; BI 104; BUDESONIDE; CHEMOKINE RECEPTOR ANTAGONIST; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; DAPSONE; DEXAMETHASONE; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; GINKGO BILOBA EXTRACT; GLYCYRRHIZA EXTRACT; HYDROXYCHLOROQUINE; IPRATROPIUM BROMIDE; KI 19003; METHOTREXATE; MONTELUKAST; NAFAMSTAT MESILATE; OMALIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AIRWAY REMODELING; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ANTISENSE THERAPY; ASTHMA; BINDING AFFINITY; BRONCHOSPASM; CATARACT; CELL MEMBRANE; CELL MIGRATION; CELL NUCLEUS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; CRYSTAL STRUCTURE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; CYTOPLASM; DIMERIZATION; DNA BINDING; DNA TRANSCRIPTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GERIATRIC DISORDER; GLAUCOMA; GOLD STANDARD; GROWTH DISORDER; HISTONE ACETYLATION; HUMAN; LIPOPHILICITY; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOLECULAR INTERACTION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OXIDATIVE STRESS; PHYTOTHERAPY; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RESPIRATORY TRACT ALLERGY; REVIEW; STEROID BINDING; SUBSTITUTION THERAPY; UPREGULATION;

ASTHMA; CORTICOSTEROIDS; DRUG RESISTANCE;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG DESIGN; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84878710823     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.5.1950149     Document Type: Review

References (116)

1. Petersen, K.D. Impact of allergy and asthma on quality of life and comparison with other diseases. Drugs Today (Barc) 2008, 44(Suppl. B): 17-8.
2. Barnes, P.J., Chung, K.F., Page, C.P. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998, 50(4): 515-96. (Pubitemid 29028812)
3. Myers, T.R., Tomasio, L. Asthma: 2015 and beyond. Respir Care 2011, 56(9): 1389-407.
4. Hafezi-Moghadam, A., Simoncini, T., Yang, Z. et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002, 8(5): 473-9. (Pubitemid 34546749)
5. de Coupade, C., Solito, E., Levine, J.D. Dexamethasone enhances interaction of endogenous annexin 1 with L-selectin and triggers shedding of L-selectin in the monocytic cell line U-937. Br J Pharmacol 2003, 140(1): 133-45. (Pubitemid 37175839)
6. Horvath, G., Lieb, T., Conner, G.E., Salathe, M., Wanner, A. Steroid sensitivity of norepinephrine uptake by human bronchial arterial and rabbit aortic smooth muscle cells. Am J Respir Cell Mol Biol 2001, 25(4): 500-6. (Pubitemid 33037683)
7. Horvath, G., Sutto, Z., Torbati, A., Conner, G.E., Salathe, M., Wanner, A. Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003, 285(4): L829-37. (Pubitemid 37158829)
8. Ewing, P., Ryrfeldt, A., Sjoberg, C.O., Andersson, P., Edsbacker, S., Gerde, P. Vasoconstriction after inhalation of budesonide: a study in the isolated and perfused rat lung. Pulm Pharmacol Ther 2010, 23(1): 9-14.
9. Barnes, P.J., Adcock, I.M. How do corticosteroids work in asthma? Ann Intern Med 2003, 139(5, Pt. 1): 359-70. (Pubitemid 38124591)
10. Hench, P.S., Kendall, E.C., et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949, 24(8): 181-97.
11. Barnes, P.J., Pedersen, S., Busse, W.W. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998, 157(3, Pt. 2): S1-53.
12. Barnes, N.C. Reducing oral steroids with inhaled steroids: is that all that can be achieved? Chest 2006, 129(5): 1124-5.
13. Ho, G.T., Moodie, F.M., Satsangi, J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003, 52(5): 759-66. (Pubitemid 36528884)
14. Farrell, R.J., Menconi, M.J., Keates, A.C., Kelly, C.P. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment Pharmacol Ther 2002, 16(5): 1021-31. (Pubitemid 34461774)
15. Montano, E., Schmitz, M., Blaser, K., Simon, H.U. P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma. J Investig Allergol Clin Immunol 1996, 6(1): 14-21. (Pubitemid 26093606)
16. Kopriva, F., Dzubak, P., Potesil, J., Hajduch, M. The antiinflammatory effects of inhaled corticosteroids versus antileukotrienes on the lymphocyte P-glycoprotein (PGP) expression in asthmatic children. J Asthma 2009, 46(4): 366-70.
17. Cohen, J.S., Benton, A.S., Nwachukwu, F., Ozedirne, T., Teach, S.J., Freishtat, R.J. P-glycoprotein transporter expression on a549 respiratory epithelial cells is positively correlated with intracellular dexamethasone levels. J Investig Med 2010, 58(8): 991-4.
18. Leung, D.Y., Hamid, Q., Vottero, A. et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997, 186(9): 1567-74. (Pubitemid 27479816)
19. Hamid, Q.A., Wenzel, S.E., Hauk, P.J. et al. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 1999, 159(5, Pt. 1): 1600-4. (Pubitemid 29227876)
20. Bodwell, J.E., Webster, J.C., Jewell, C.M., Cidlowski, J.A., Hu, J.M., Munck, A. Glucocorticoid receptor phosphorylation: overview, function and cell cycle-dependence. J Steroid Biochem Mol Biol 1998, 65(1-6): 91-9. (Pubitemid 28335594)
21. Szefler, S.J., Leung, D.Y. Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management. Eur Respir J 1997, 10(7): 1640-7. (Pubitemid 27311085)
22. Spahn, J.D., Szefler, S.J., Surs, W., Doherty, D.E., Nimmagadda, S.R., Leung, D.Y. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptorbinding affinity. J Immunol 1996, 157(6): 2654-9. (Pubitemid 126450482)
23. Irusen, E., Matthews, J.G., Takahashi, A., Barnes, P.J., Chung, K.F., Adcock, I.M. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002, 109(4): 649-57. (Pubitemid 34327193)
24. Ismaili, N., Garabedian, M.J. Modulation of glucocorticoid receptor function via phosphorylation. Ann N Y Acad Sci 2004, 1024: 86-101. (Pubitemid 38879595)
25. Corrigan, C.J., Brown, P.H., Barnes, N.C., Szefler, S.J., Tsai, J.J., Frew, A.J., Kay, A.B. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991, 144(5): 1016-25.
26. Adcock, I.M., Lane, S.J., Brown, C.R., Lee, T.H., Barnes, P.J. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 1995, 182(6): 1951-8.
27. Biggadike, K., Bledsoe, R.K., Hassell, A.M., Kirk, B.E., McLay, I.M., Shewchuk, L.M., Stewart, E.L. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem 2008, 51(12): 3349-52. (Pubitemid 351874991)
28. Adcock, I.M., Nasuhara, Y., Stevens, D.A., Barnes, P.J. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol 1999, 127(4): 1003-11. (Pubitemid 29295361)
29. Tamm, M., Richards, D.H., Beghe, B., Fabbri, L. Inhaled corticosteroid and long-acting beta(2)-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med 2012, 106(Suppl. 1): S9-S19.
30. Vianna, E.O., Martin, R.J. Bronchodilators and corticosteroids in the treatment of asthma. Drugs Today (Barc) 1998, 34(3): 203-23. (Pubitemid 28168443)
31. Adcock, I.M., Stevens, D.A., Barnes, P.J. Interactions of glucocorticoids and beta 2-agonists. Eur Respir J 1996, 9(1): 160-8.
32. Usmani, O.S., Ito, K., Maneechotesuwan, K., Ito, M., Johnson, M., Barnes, P.J., Adcock, I.M. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005, 172(6): 704-12. (Pubitemid 41324225)
33. Reid, D.W., Ward, C., Wang, N., Zheng, L., Bish, R., Orsida, B., Walters, E.H. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J 2003, 21(6): 994-9. (Pubitemid 36675616)
34. Spoelstra, F.M., Postma, D.S., Hovenga, H., Noordhoek, J.A., Kauffman, H.F. Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax 2002, 57(3): 237-41. (Pubitemid 34214410)
35. Peters, S.P., Kunselman, S.J., Icitovic, N. et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010, 363(18): 1715-26.
36. Iwamoto, H., Yokoyama, A., Shiota, N., Shoda, H., Haruta, Y., Hattori, N., Kohno, N. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 2008, 31(6): 1379-80.
37. Magnussen, H., Bugnas, B., van Noord, J., Schmidt, P., Gerken, F., Kesten, S. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 2008, 102(1): 50-6. (Pubitemid 350151827)
38. Sun, X., Li, Q., Gong, Y., Ren, L., Wan, H., Deng, W. Low-dose theophylline restores corticosteroid responsiveness in rats with smoke-induced airway inflammation. Can J Physiol Pharmacol 2012, 90(7): 895-902.
39. van Mastbergen, J., Jolas, T., Allegra, L., Page, C.P. The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism. Pulm Pharmacol Ther 2012, 25(1): 55-61.
40. Christie, P. Roflumilast: a selective phosphodiesterase 4 inhibitor. Drugs Today (Barc) 2005, 41(10): 667-75. (Pubitemid 43074776)
41. Cho, J.Y. Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic. Korean J Intern Med 2011, 26(4): 367-83.
42. Zielen, S., Lieb, A., De La Motte, S. et al. Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma. Int Arch Allergy Immunol 2013, 160(1): 102-10.
43. Thomson, N.C., Chaudhuri, R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med 2012, 6: 27-40.
44. Casale, T.B. Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis. Drugs Today (Barc) 2004, 40(4): 367-76. (Pubitemid 38724779)
45. Chipps, B.E., Figliomeni, M., Spector, S. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Allergy Asthma Proc 2012, 33(5): 377-85.
46. Storms, W., Bowdish, M.S., Farrar, J.R. Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review. Allergy Asthma Proc 2012, 33(2): 172-7.
47. Rubin, A.S., Souza-Machado, A., Andradre-Lima, M., Ferreira, F., Honda, A., Matozo, T.M. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma 2012, 49(3): 288-93.
48. Menzella, F., Facciolongo, N., Piro, R. et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year followup. Ther Adv Respir Dis 2012, 6(2): 87-95.
49. de Llano, L.P., Vennera, M.D., Alvarez, F.J. et al. Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry. J Asthma 2013, 50(3): 296-301.
50. Brodlie, M., McKean, M.C., Moss, S., Spencer, D.A. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 2012, 97(7): 604-9.
51. Kuhl, K., Hanania, N.A. Targeting IgE in asthma. Curr Opin Pulm Med 2012, 18(1): 1-5.
52. Yamada, T., Takahashi, Y., Ishizaki, M. et al. Effects of RS-601, a novel leukotriene D(4)/thromboxane A(2) dual receptor antagonist, on asthmatic responses in guinea pigs. Pharmacology 2003, 69(1): 51-8. (Pubitemid 36928724)
53. Bozek, A., Warkocka-Szoltysek, B., Filipowska-Gronska, A., Jarzab, J. Montelukast as an add-on therapy to inhaled corti-costeroids in the treatment of severe asthma in elderly patients. J Asthma 2012, 49(5): 530-4.
54. Adachi, M., Taniguchi, H., Tohda, Y., Sano, Y., Ishine, T., Smugar, S.S., Hisada, S. The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients. J Asthma 2012, 49(6): 649-56.
55. Price, D., Popov, T.A., Bjermer, L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol 2013, 131(3): 763-71.
56. Philip, G., Villaran, C., Shah, S.R., Vandormael, K., Smugar, S.S., Reiss, T.F. The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. J Asthma 2011, 48(5): 495-502.
57. van Tilborg, M.A., Bonvin, A.M., Hard, K. et al. Structure refinement of the glucocorticoid receptor-DNA binding domain from NMR data by relaxation matrix calculations. J Mol Biol 1995, 247(4): 689-700.
58. Baumann, H., Paulsen, K., Kovacs, H., Berglund, H., Wright, A.P., Gustafsson, J.A., Hard, T. Refined solution structure of the glucocorticoid receptor DNA-binding domain. Biochemistry 1993, 32(49): 13463-71. (Pubitemid 24020220)
59. Wickert, L., Selbig, J. Structural analysis of the DNA-binding domain of alternatively spliced steroid receptors. J Endocrinol 2002, 173(3): 429-36. (Pubitemid 34704714)
60. Biggadike, K., Bledsoe, R.K., Coe, D.M. et al. Design and xray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor. Proc Natl Acad Sci U S A 2009, 106(43): 18114-9.
61. Bledsoe, R.K., Montana, V.G., Stanley, T.B. et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002, 110(1): 93-105. (Pubitemid 34874609)
62. Kohn, J.A., Deshpande, K., Ortlund, E.A. Deciphering modern glucocorticoid cross-pharmacology using ancestral corticosteroid receptors. J Biol Chem 2012, 287(20): 16267-75.
63. Cato, A.C., Schacke, H., Sterry, W., Asadullah, K. The glucocorticoid receptor as target for classic and novel anti-inflammatory therapy. Curr Drug Targets Inflamm Allergy 2004, 3(4): 347-53. (Pubitemid 39534771)
64. Newton, R., Holden, N.S. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 2007, 72(4): 799-809. (Pubitemid 47481403)
65. Hudson, A.R., Roach, S.L., Higuchi, R.I. Recent developments in the discovery of selective glucocorticoid receptor modulators (SGRMs). Curr Top Med Chem 2008, 8(9): 750-65. (Pubitemid 351982564)
66. Schacke, H., Schottelius, A., Docke, W.D. et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 2004, 101(1): 227-32. (Pubitemid 38084232)
67. Takahashi, H., Razavi, H., Thomson, D. Recent progress in the discovery of novel glucocorticoid receptor modulators. Curr Top Med Chem 2008, 8(6): 521-30. (Pubitemid 351982593)
68. Clackers, M., Coe, D.M., Demaine, D.A. et al. Non-steroidal glucocorticoid agonists: the discovery of aryl pyrazoles as Aring mimetics. Bioorg Med Chem Lett 2007, 17(17): 4737-45. (Pubitemid 47187714)
69. Barnett, H.A., Coe, D.M., Cooper, T.W. et al. Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists. Bioorg Med Chem Lett 2009, 19(1): 158-62.
70. De Bosscher, K., Haegeman, G., Elewaut, D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 2010, 10(4): 497-504.
71. Valapour, M., Guo, J., Schroeder, J.T., Keen, J., Cianferoni, A., Casolaro, V., Georas, S.N. Histone deacetylation inhibits IL4 gene expression in T cells. J Allergy Clin Immunol 2002, 109(2): 238-45. (Pubitemid 34158287)
72. Kagoshima, M., Ito, K., Cosio, B., Adcock, I.M. Glucocorticoid suppression of nuclear factor-kappa B: a role for histone modifications. Biochem Soc Trans 2003, 31(Pt. 1): 60-5. (Pubitemid 36241397)
73. Jee, Y.K., Gilmour, J., Kelly, A. et al. Repression of interleukin-5 transcription by the glucocorticoid receptor targets GATA3 signaling and involves histone deacetylase recruitment. J Biol Chem 2005, 280(24): 23243-50. (Pubitemid 40853236)
74. Ichikawa, T., Hayashi, R., Suzuki, K. et al. Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma. Respirology 2013, 18(2): 332-9.
75. Milne, J.C., Lambert, P.D., Schenk, S. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450(7170): 712-6. (Pubitemid 350207685)
76. Rajendrasozhan, S., Yang, S.R., Kinnula, V.L., Rahman, I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177(8): 861-70. (Pubitemid 351600664)
77. Araki, T., Sasaki, Y., Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004, 305(5686): 1010-3. (Pubitemid 39071777)
78. Kumar, A., Lnu, S., Malya, R., Barron, D., Moore, J., Corry, D.B., Boriek, A.M. Mechanical stretch activates nuclear factor-kappaB, activator protein-1, and mitogen-activated protein kinases in lung parenchyma: implications in asthma. FASEB J 2003, 17(13): 1800-11. (Pubitemid 37214774)
79. Underwood, D.C., Osborn, R.R., Kotzer, C.J. et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000, 293(1): 281-8. (Pubitemid 30180950)
80. Duan, W., Chan, J.H., McKay, K. et al. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2005, 171(6): 571-8. (Pubitemid 40365411)
81. Chopra, P., Kanoje, V., Semwal, A., Ray, A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs 2008, 17(10): 1411-25.
82. Millan, D.S., Bunnage, M.E., Burrows, J.L. et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem 2011, 54(22): 7797-814.
83. Komai, M., Tanaka, H., Nagao, K. et al. A novel CCchemokine receptor 3 antagonist, Ki19003, inhibits airway eosinophilia and subepithelial/ peribronchial fibrosis induced by repeated antigen challenge in mice. J Pharmacol Sci 2010, 112(2): 203-13.
84. Ishizaki, M., Tanaka, H., Kajiwara, D., Toyohara, T., Wakahara, K., Inagaki, N., Nagai, H. Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma. J Pharmacol Sci 2008, 108(3): 355-63.
85. Bodera, P. Immunostimulatory oligonucleotides. Recent Pat Inflamm Allergy Drug Discov 2011, 5(1): 87-93.
86. Gupta, G.K., Agrawal, D.K. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. Bio Drugs 2010, 24(4): 225-35.
87. Hirose, I., Tanaka, H., Takahashi, G. et al. Immunomo-dulatory effects of CpG oligodeoxynucleotides on house dust mite-induced airway inflammation in mice. Int Arch Allergy Immunol 2008, 147(1): 6-16.
88. Molfino, N.A. Targeting of eosinophils in asthma. Expert Opin Biol Ther 2012, 12(7): 807-9.
89. Corren, J. Anti-interleukin-5 antibody therapy in asthma and allergies. Curr Opin Allergy Clin Immunol 2011, 11(6): 565-70.
90. Dube, J., Chakir, J., Dube, C., Grimard, Y., Laviolette, M., Boulet, L.P. Synergistic action of endothelin (ET)-1 on the activation of bronchial fibroblast isolated from normal and asthmatic subjects. Int J Exp Pathol 2000, 81(6): 429-37. (Pubitemid 32291183)
91. Kassuya, C.A., Rogerio, A.P., Calixto, J.B. The role of ET(A) and ET(B) receptor antagonists in acute and allergic inflammation in mice. Peptides 2008, 29(8): 1329-37.
92. Guntur, V.P., Reinero, C.R. The potential use of tyrosine kinase inhibitors in severe asthma. Curr Opin Allergy Clin Immunol 2012, 12(1): 68-75.
93. Lee-Fowler, T.M., Guntur, V., Dodam, J., Cohn, L.A., DeClue, A.E., Reinero, C.R. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int Arch Allergy Immunol 2012, 158(4): 369-74.
94. Comet, R., Domingo, C., Larrosa, M., Moron, A., Rue, M., Amengual, M.J., Marin, A. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Respir Med 2006, 100(3): 411-9. (Pubitemid 43239875)
95. Evans, D.J., Cullinan, P., Geddes, D.M. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001(2): CD002985.
96. Lock, S.H., Kay, A.B., Barnes, N.C. Double-blind, placebocontrolled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996, 153(2): 509-14. (Pubitemid 26051322)
97. Dykewicz, M.S. Newer and alternative non-steroidal treatments for asthmatic inflammation. Allergy Asthma Proc 2001, 22(1): 11-5.
98. Desai, D., Brightling, C. TNF-alpha antagonism in severe asthma? Recent Pat Inflamm Allergy Drug Discov 2010, 4(3): 193-200.
99. Xystrakis, E., Kusumakar, S., Boswell, S. et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006, 116(1): 146-55. (Pubitemid 43121799)
100. Balaha, M.F., Tanaka, H., Yamashita, H., Abdel Rahman, M.N., Inagaki, N. Oral Nigella sativa oil ameliorates ovalbumin-induced bronchial asthma in mice. Int Immunopharmacol 2012, 14(2): 224-31.
101. Schwartz, J., Weiss, S.T. Caffeine intake and asthma symptoms. Ann Epidemiol 1992, 2(5): 627-35.
102. Kim, D.H., Phillips, J.F., Lockey, R.F. Oral curcumin supplementation in patients with atopic asthma. Allergy Rhinol (Providence) 2011, 2(2): e51-3.
103. Guinot, P., Brambilla, C., Duchier, J., Braquet, P., Bonvoisin, B., Cournot, A. Effect of BN 52063, a specific PAF-acether antagonist, on bronchial provocation test to allergens in asthmatic patients. A preliminary study. Prostaglandins 1987, 34(5): 723-31. (Pubitemid 18010598)
104. Hofmann, D., Hecker, M., Volp, A. Efficacy of dry extract of ivy leaves in children with bronchial asthma-a review of randomized controlled trials. Phytomedicine 2003, 10(2-3): 213-20. (Pubitemid 36433221)
105. Shin, Y.W., Bae, E.A., Lee, B., Lee, S.H., Kim, J.A., Kim, Y.S., Kim, D.H. In vitro and in vivo antiallergic effects of Glycyrrhiza glabra and its components. Planta Medica 2007, 73(3): 257-61. (Pubitemid 46917478)
106. Lee, M.R. The history of Ephedra (ma-huang). J R Coll Physicians Edinb 2011, 41(1): 78-84.
107. Balaha, M.F., Tanaka, H., Yamashita, H., Abdel Rahman, M.N., Inagaki, N. Oral Nigella sativa oil ameliorates ovalbumin-induced bronchial asthma in mice. Agents Actions 2012, 14(2): 224-31.
108. Dorsch, W., Weber, J. Prevention of allergen-induced bronchial obstruction in sensitized guinea pigs by crude alcoholic onion extract. 1984, 14(5-6): 626-9.
109. Kim, D.Y., Yang, W.M. Panax ginseng ameliorates airway inflammation in an ovalbumin-sensitized mouse allergic asthma model. J Ethnopharmacol 2011, 136(1): 230-5.
110. Hamasaki, Y., Kobayashi, I., Hayasaki, R. et al. The Chinese herbal medicine, shinpi-to, inhibits IgE-mediated leukotriene synthesis in rat basophilic leukemia-2H3 cells. Indian J Med Res 1997, 56(2): 123-31. (Pubitemid 27217640)
111. Gupta, S., George, P., Gupta, V., Tandon, V.R., Sundaram, K.R. Tylophora indica in bronchial asthma-a double blind study. Med J Aust 1979, 69: 981-9. (Pubitemid 9239262)
112. Hodge, L., Salome, C.M., Peat, J.K., Haby, M.M., Xuan, W., Woolcock, A.J. Consumption of oily fish and childhood asthma risk. Eur Respir J 1996, 164(3): 137-40. (Pubitemid 26051104)
113. Hill, J., Micklewright, A., Lewis, S., Britton, J. Investigation of the effect of short-term change in dietary magnesium intake in asthma. Clin Exp Allergy 1997, 10(10): 2225-9. (Pubitemid 27479540)
114. Hoffmann, P.R. Asthma in children and nutritional selenium get another look. Ann N Y Acad Sci 2012, 42(4): 488-9.
115. Ubbink, J.B., Vermaak, W.J., Delport, R., Serfontein, W.J., Bartel, P. The relationship between vitamin B6 metabolism, asthma, and theophylline therapy. Acta Med Iran 1990, 585: 285-94. (Pubitemid 20175905)
116. Nadi, E., Tavakoli, F., Zeraati, F., Goodarzi, M.T., Hashemi, S.H. Effect of vitamin C administration on leukocyte vitamin C level and severity of bronchial asthma. 2012, 50(4): 233-8.